Press Release:

CYTOCHROMA’S VITAMIN D ANALOG SHOWS PROMISING RESULTS
IN MULTIPLE SCLEROSIS MODEL

Markham, Ontario, Canada — June 7, 2006 — Cytochroma Inc. today announced positive results of one of its lead compounds in a multiple sclerosis disease model (the Experimental Autoimmune Encephalomyelitis or EAE model). The study showed that CTA012, a proprietary vitamin D analog, was found to reduce the overall severity of the disease. In addition, CTA012 was well tolerated and more efficacious than the natural bioactive form of vitamin D. Details of the study were recently presented in Victoria, British Columbia at the 13th Vitamin D Workshop.

"There is a growing body of evidence that suggests vitamin D exerts a protective effect in multiple sclerosis both in the development of the disease and in limiting its progression.” stated Martin Petkovich, Cytochroma’s CSO. “By using our novel vitamin D analogs, we believe we have the potential to give multiple sclerosis patients a safe means to control their disease symptoms.”

In the EAE model, CTA012 was able to exhibit dose-dependant suppression of clinical signs as well as key proinflammatory markers such as gamma-interferon secretion and immune cell infiltration of the central nervous system (CNS). Cytochroma plans to further investigate this novel vitamin D analog in determining its suitability to treat multiple sclerosis.

About CTA012

CTA012 is a novel vitamin D analog with a dual mechanism of action. It is a strong activator of the vitamin D signaling pathway and also a potent inhibitor of CYP24 activity (the enzyme responsible for the breakdown of vitamin D). CTA012 was specifically designed by Prof. Gary H. Posner and is protected under patents and patent applications exclusively licensed to Cytochroma Inc. from the Johns Hopkins University. Cytochroma Inc. – Next Generation Drugs Combining Superior Safety With Efficacy 2

About Multiple Sclerosis

Multiple Sclerosis (MS) is a chronic disease of the CNS. MS is a progressive, often disabling disease in which the immune system is believed to attack the myelin covering the nerves resulting in disruption of signals sent and received by the CNS. Symptoms of MS include vision or dexterity problems, numbness or tingling sensations which may increase in severity to eventually include a partial or complete loss of vision or mobility. Current treatments have serious side effects and some carry significant risks. There is no cure for multiple sclerosis.

About Cytochroma Inc.

Cytochroma Inc. is a specialty drug development company targeting hyperproliferative disorders, autoimmune diseases and chronic kidney disease. The company is currently focused on developing and commercializing innovative vitamin D analogs and is in or about to enter clinical trials in psoriasis, secondary hyperparathyroidism, autoimmune disorders and cancer. For more information, please visit www.cytochroma.com.

For information contact:

Sheldon Kawarsky, Ph.D.
Director, Business Development
Cytochroma Inc.
330 Cochrane Drive
Markham, Ontario L3R 8E4
CANADA
Phone: (905) 479-5306 ext. 337
Fax: (905) 479-1287
sheldon.kawarsky@cytochroma.com

< go back >